Safety, Tolerability and PK of Imeglimin in Japanese Volunteers

Inclusion Criteria: * Male or female Japanese subjects, deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine * Body mass index in the range 18.0-25.0 kg/m2 * Willing to use reliable contraception * Able to give fully informed written consent. Exclusion Criteria: * Pregnant or lactating woman, or sexually active woman of child-bearing potential not using reliable contraception * Clinically relevant abnormal findings at the screening assessment * Clinically significant vital signs outside the acceptable range at screening * Clinically relevant abnormal medical history, surgery or concurrent medical condition * Acute or chronic illness * Estimated glomerular filtration rate less than 80 mL/min/1.73 m2 * Severe adverse reaction to any drug or sensitivity to the trial medication or its components * Significant food allergy; vegetarian or vegan * Use of vitamins, herbal medicines, or over-the-counter medication (with the exception of paracetamol \[acetaminophen\]) within 7 days before first dose of trial medication, or prescribed medication during the 14 days before first dose of trial medication * Participation in other clinical trials of unlicensed or prescription medicines, or loss of more than 400 mL blood, within the 3 months before first dose of trial medication * Drug or alcohol abuse * Smoking of more than 5 cigarettes daily * Possibility that subject will not cooperate * Positive test for hepatitis B \& C, HIV * Objection by a General Practitioner.